Seroatlas · Human Serome Atlas

AKR7A3

Aldo-keto reductase family 7 member A3

Also known as: ARK73_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: O95154
Gene: AKR7A3
Ensembl: ENSG00000162482
Chromosome: 1
Canonical length: 331 aa
Protein class: Metabolic proteins, Predicted intracellular proteins
Subcellular location: Golgi apparatus,Cytosol
Quaternary structure: Homodimer

OverviewNCBI Gene

Aldo-keto reductases, such as AKR7A3, are involved in the detoxification of aldehydes and ketones.[supplied by OMIM, Apr 2004]

Canonical amino-acid sequenceUniProt

331 residues, UniProt reviewed canonical sequence.

>O95154|AKR7A3
     1  MSRQLSRARP ATVLGAMEMG RRMDAPTSAA VTRAFLERGH TEIDTAFVYS EGQSETILGG
    61  LGLRLGGSDC RVKIDTKAIP LFGNSLKPDS LRFQLETSLK RLQCPRVDLF YLHMPDHSTP
   121  VEETLRACHQ LHQEGKFVEL GLSNYAAWEV AEICTLCKSN GWILPTVYQG MYNAITRQVE
   181  TELFPCLRHF GLRFYAFNPL AGGLLTGKYK YEDKNGKQPV GRFFGNTWAE MYRNRYWKEH
   241  HFEGIALVEK ALQAAYGASA PSMTSATLRW MYHHSQLQGA HGDAVILGMS SLEQLEQNLA
   301  AAEEGPLEPA VVDAFNQAWH LVTHECPNYF R

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against AKR7A3 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Intracellular
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.23
Highest tissue expression: 400 nTPM

Expression across tissuesHPA

Tissue

pancreas: 400 nTPM
stomach: 306 nTPM
duodenum: 234 nTPM
liver: 218 nTPM
small intestine: 136 nTPM
kidney: 86 nTPM

Single-cell type

parietal cells: 1,425 nCPM
enterocytes: 955 nCPM
gastric chief cells: 262 nCPM
enteric transient amplifying cells: 182 nCPM
pancreatic acinar cells: 150 nCPM
colonocytes: 134 nCPM

Immune cell

plasmacytoid DC: 0.3 nTPM
basophil: 0 nTPM
classical monocyte: 0 nTPM
eosinophil: 0 nTPM
gdT-cell: 0 nTPM
intermediate monocyte: 0 nTPM

Brain region

choroid plexus: 35 nTPM
hippocampal formation: 6.8 nTPM
thalamus: 6.2 nTPM
midbrain: 6 nTPM
cerebellum: 5.7 nTPM
medulla oblongata: 5.6 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.93
gnomAD pLI: 0
gnomAD missense Z: -0.17
DepMap mean gene effect: -0.21
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of AKR7A3 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

AKR7A2

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads AKR7A3 as an antibody target. Whether an autoantibody or antibody against AKR7A3 could matter depends on whether native AKR7A3 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

AKR7A3 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label AKR7A3 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...